Odyssey Health reports positive initial Phase I results for concussion drug PRV-002

Odyssey Health, Inc.

First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.
Phase I trial ongoing with 48 healthy subjects in single and multi-ascending dose components.
Company plans to present Phase I data to FDA, then initiate Phase II trial in US starting with military.
Concussion affects over 3 million annually in US; no FDA-approved treatment currently exists.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.